Inebilizumab reduces exacerbations, rescue therapy in generalized myasthenia gravis

Patients with generalized myasthenia gravis taking inebilizumab were less likely to experience exacerbations or need rescue therapy compared with a placebo group, according to research published in JAMA Neurology. The implications are important for patients looking to avoid exacerbations, which often require hospitalization and are associated with significant morbidity, said Richard J. Nowak, MD,